Lysosome‐Associated Membrane Protein 3 Induces Lysosome‐Dependent Cell Death by Impairing Autophagic Caspase 8 Degradation in the Salivary Glands of Individuals With Sjögren's Disease

Lysosome‐associated membrane protein 3 (LAMP3) overexpression is implicated in the development and progression of Sjögren's disease (SjD) by inducing lysosomal membrane permeabilization (LMP) and apoptotic cell death in salivary gland epithelium. The aim of this study was to clarify the molecular details of LAMP3‐induced lysosome‐dependent cell death and to test lysosomal biogenesis as a therapeutic intervention.

[1]  J. Chiorini,et al.  Lysosomal exocytosis of HSP70 stimulates monocytic BMP6 expression in Sjögren’s syndrome , 2022, The Journal of clinical investigation.

[2]  Min Han,et al.  Clinical and Pathological Implications of Increases in Tonsillar CD19+CD5+ B Cells, CD208+ Dendritic Cells, and IgA1-positive Cells of Immunoglobulin A Nephropathy , 2022, Current Medical Science.

[3]  J. Chiorini,et al.  HCV Infection Alters Salivary Gland Histology and Saliva Composition , 2022, Journal of dental research.

[4]  Daniel de Bortoli Teixeira,et al.  GLP-1a: Going beyond Traditional Use , 2022, International journal of molecular sciences.

[5]  J. Chiorini,et al.  LAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilization , 2021, Autophagy.

[6]  G. Cavalli,et al.  Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome , 2021, Arthritis & rheumatology.

[7]  J. Chiorini,et al.  Sclerosing Sialadenitis Is Associated With Salivary Gland Hypofunction and a Unique Gene Expression Profile in Sjögren’s Syndrome , 2021, Frontiers in Immunology.

[8]  Jun Xu,et al.  Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta‐analysis , 2021, Journal of clinical pharmacy and therapeutics.

[9]  J. Chiorini,et al.  Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren’s syndrome-like phenotype in mice , 2021, Annals of the Rheumatic Diseases.

[10]  Mark R. Marten,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 , 2021, Autophagy.

[11]  Yuanyuan Xiao,et al.  Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway , 2020, Frontiers in Cell and Developmental Biology.

[12]  S. Matus,et al.  Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjögren's syndrome. , 2020, Rheumatology.

[13]  A. Folgori,et al.  Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 , 2020, bioRxiv.

[14]  R. Priori,et al.  Autophagy occurs in lymphocytes infiltrating Sjögren’s syndrome minor salivary glands and correlates with histological severity of salivary gland lesions , 2020, Arthritis Research & Therapy.

[15]  J. Chiorini,et al.  LAMP3 induces apoptosis and autoantigen release in Sjögren’s syndrome patients , 2020, Scientific Reports.

[16]  T. Atsumi,et al.  How should rheumatologists manage glucocorticoid-induced hyperglycemia? , 2020, Modern rheumatology.

[17]  J. Singh,et al.  Serious infections in Sjögren's syndrome patients: a national U.S. study. , 2020, Clinical and experimental rheumatology.

[18]  W. Banks,et al.  Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. , 2020, Biochemical pharmacology.

[19]  J. Chiorini,et al.  Autophagy as a modulator of cell death machinery , 2020, Cell Death & Disease.

[20]  N. Zhang,et al.  Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren’s syndrome in mice , 2020, Scientific Reports.

[21]  S. Muller,et al.  Correction of autophagy impairment inhibits pathology in the NOD.H-2h4 mouse model of primary Sjögren's syndrome. , 2020, Journal of autoimmunity.

[22]  Binghui Li,et al.  Caspase-8 Induces Lysosome-Associated Cell Death in Cancer Cells. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  X. Mariette,et al.  EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies , 2019, Annals of the rheumatic diseases.

[24]  J. Chiorini,et al.  Targeting primary Sjögren’s syndrome , 2019, Modern rheumatology.

[25]  S. Muller,et al.  Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. , 2018, Journal of autoimmunity.

[26]  Y. Ciribilli,et al.  LAMPs: Shedding light on cancer biology. , 2017, Seminars in oncology.

[27]  R. Priori,et al.  CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren’s syndrome patients and correlates with focus score and disease activity , 2017, Arthritis Research & Therapy.

[28]  P. Lovat,et al.  Glucagon-Like Peptide 1 Protects Pancreatic β-Cells From Death by Increasing Autophagic Flux and Restoring Lysosomal Function , 2017, Diabetes.

[29]  L. Criswell,et al.  2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient Cohorts , 2017, Arthritis & rheumatology.

[30]  J. Chiorini,et al.  Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice , 2016, Proceedings of the National Academy of Sciences.

[31]  I. Gromova,et al.  Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay , 2015, Autophagy.

[32]  R. Ono.  [GLP-1 receptor expression in rat major salivary glands and the effects of bilateral maxillary molar extraction on its expression]. , 2015, Kokubyo Gakkai zasshi. The Journal of the Stomatological Society, Japan.

[33]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[34]  Jennifer M. Trujillo,et al.  Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. , 2015, The Annals of pharmacotherapy.

[35]  J. Baker,et al.  Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome. , 2014, Clinical and experimental rheumatology.

[36]  Y. Shinomura,et al.  Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist , 2014, Nature Reviews Rheumatology.

[37]  G. Illei,et al.  Association of bone morphogenetic protein 6 with exocrine gland dysfunction in patients with Sjögren's syndrome and in mice. , 2013, Arthritis and rheumatism.

[38]  T. Saha.  LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy , 2012, Autophagy.

[39]  J. Stone,et al.  Treatment of primary Sjögren syndrome: a systematic review. , 2010, JAMA.

[40]  T. Sumida,et al.  Efficacy prediction of cevimeline in patients with Sjögren’s syndrome , 2007, Clinical Rheumatology.

[41]  P. Manganelli,et al.  Apoptosis and Sjögren syndrome. , 2003, Seminars in arthritis and rheumatism.

[42]  A. Cuervo,et al.  A Receptor for the Selective Uptake and Degradation of Proteins by Lysosomes , 1996, Science.

[43]  S. R. Terlecky,et al.  A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. , 1989, Science.

[44]  S. Aits.  Methods to Detect Loss of Lysosomal Membrane Integrity. , 2019, Methods in molecular biology.